Navidea Biopharmaceuticals Names Craig A. Dais As CFO
Portfolio Pulse from Benzinga Newsdesk
Navidea Biopharmaceuticals has appointed Craig A. Dais as its new Chief Financial Officer. Dais will report directly to the company's Chief Medical Officer. This move aligns with Navidea's 'Fix, Fund, Propel' strategy to advance innovative technology to market.
July 27, 2023 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Navidea Biopharmaceuticals has appointed a new CFO, Craig A. Dais. This move aligns with the company's strategy to advance innovative technology to market.
The appointment of a new CFO is a significant event for a company. However, it's unclear how this will affect Navidea's stock price in the short term. The new CFO's performance and the company's future financial decisions will determine the impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100